{"entity":{"id":"nct05050006","kind":"trial","name":"ITIL-168 in Advanced Melanoma","aka":[],"tldr":"A phase 2 trial of ITIL-168 run by Instil Bio, terminated.","summary":"ITIL-168 in Advanced Melanoma is a phase 2 interventional study registered as NCT05050006 by Instil Bio, with 29 participants enrolled, started 2021-10-07. Conditions recorded: Advanced Cutaneous Melanoma. Interventions recorded: ITIL-168.","status":"historic","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT05050006","url":"https://clinicaltrials.gov/study/NCT05050006"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["itil-168"],"companies":["instil-bio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05050006","phase":"2","setting":"A Phase 2, Open-label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects With Advanced Melanoma (DELTA-1)","sponsor":"Instil Bio","enrolled":29,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05050006/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"itil-168","kind":"drug","name":"ITIL-168","route":"/drugs/itil-168/"}],"company":[{"id":"instil-bio","kind":"company","name":"Instil Bio","route":"/companies/instil-bio/"}]}}